Citadel Advisors’s Orphazyme A/S ORPH Stock Holding History

Citadel Advisors’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,400	Closed	-$64K	–	15183
2021 Q4	$64K	Sell	26,400 -16,500	-38%	-$58.3K	﹤0.01%	13106
2021 Q3	$176K	Sell	42,900 -155,600	-78%	-$801K	﹤0.01%	12162
2021 Q2	$1.46M	Buy	+198,500	New	+$1.6M	﹤0.01%	7384

Other funds holding ORPH

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's ORPH Position: Q1 2022 in Review

Citadel Advisors sold out of Orphazyme A/S (ORPH) in Q1 2022, closing a stake of 95,007 shares — an estimated $229K sold.

Citadel Advisors first reported a position in ORPH in Q3 2020 and held it in 3 quarters. The position peaked at $2.07M in Q3 2020. 4 funds tracked by Wall St. Rank hold ORPH as of Q1 2022.

Citadel Advisors reported no remaining Orphazyme A/S position as of Q1 2022 after selling out during the quarter.
Citadel Advisors sold 95,007 Orphazyme A/S shares in Q1 2022, an estimated $229K.
Citadel Advisors first reported a position in Orphazyme A/S in Q3 2020 and held it in 3 quarters.
Citadel Advisors's Orphazyme A/S position peaked at $2.07M in Q3 2020.
4 funds tracked by Wall St. Rank held Orphazyme A/S as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.